Join ISPOR  | Sign up for mailing List  | Follow Us: LinkedIn Twitter Facebook YouTube
 

Contributed Poster Presentations – Session I

ALLERGY/EYE DISORDERS
Allergy – Cost Studies
Allergy – Quality of Life Studies
Eye Diseases/Disorders – Clinical Outcomes Studies
Eye Disorders – Cost Studies
Eye Disorders - Quality of Life Studies
CARDIOVASCULAR DISEASES/DISORDERS
Cardiovascular Disease – Clinical Outcomes Studies
Cardiovascular Disease – Cost Studies
Cardiovascular Disease – Quality of Life Studies
DIABETES
Diabetes – Clinical Outcomes Studies
Diabetes – Cost Studies
Diabetes – Quality of Life Studies
GASTROINTESTINAL DISEASES/DISORDERS
Gastrointestinal Disorders – Clinical Outcomes Studies
Gastrointestinal Disorders – Cost Studies
MENTAL HEALTH
Mental Health – Clinical Outcomes Studies
Mental Health – Cost Studies
Mental Health – Quality of Life Studies
URINARY/KIDNEY DISEASES OR DISORDERS
Urinary/Kidney Diseases or Disorders – Clinical Outcomes Studies
Urinary/Kidney Diseases or Disorders - Cost Studies
Urinary/Kidney Diseases or Disorders – Quality of Life Studies
WOMEN’S & MEN’S HEALTH
Women’s & Men’s Health – Clinical Outcomes Studies
Women’s & Men’s Health – Quality of Life Studies
HEALTH CARE POLICY
Health Care Policy – Cost Evaluation Issues
Health Care Policy – Cost Studies
Health Care Policy – Compliance Studies
Health Care Policy – Drug/Price/Reimbursement Studies
Health Care Policy – Health System Studies
Health Care Policy – New Health Technology Studies
Health Care Policy – Patient Reported Outcomes Studies

ALLERGY/EYE DISORDERS
  Allergy – Cost Studies
PAE1 CHRONIC ALLERGIC RHINITIS, ECONOMICS IMPACT: FRENCH SITUATION
Myon E, Taïeb C, Pharmaco Economics & Quality of Life Department, Boulogne Billancourt, France
PAE2 THE BURDEN OF ALLERGIC CONJUNCTIVITIS IN THE UK: FINDINGS FROM A RETROSPECTIVE REVIEW OF THE GPRD DATABASE 1990-2000
Smith AF1, Martinez C2, Rubino A2, Bron AJ3, Pitt AD4, 1Alcon Laboratories Ltd and Nuffield Laboratory of Ophthalmology, University of Oxford, Hemel Hempstead, Hertfordshire, United Kingdom; 2General Practice Research Database, London, London, United Kingdom; 3Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, Oxfordshire, United Kingdom; 4University of Oxford, Oxford, Oxfordshire, United Kingdom
PAE3 THE ECONOMIC AND QUALITY OF LIFE IMPACT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN OXFORDSHIRE, ENGLAND
Smith AF, Alcon Laboratories Ltd and Nuffield Laboratory of Ophthalmology, University of Oxford, Hemel Hempstead, Hertfordshire, United Kingdom
  Allergy – Quality of Life Studies
PAE4 CONSTRUCT VALIDITY AND RELIABILITY OF THE EYE ALLERGY PATIENT IMPACT QUESTIONNAIRE (EAPIQ)
Alexander M1, Berger W2, Buchholz P3, Walt J4, Burk C5, Lee J4, Abetz L6, Arbuckle R6, 1Niagara Falls Clinical Research, Niagara Falls, Ontario, Canada; 2Southern California Resarch, Mission Viejo, CA, USA; 3Allergan, Ettlingen, Germany; 4Allergan, Irvine, CA, USA; 5CTBurk, Inc, Laguna Beach, CA, USA; 6Mapi Values, Bollington, Cheshire, United Kingdom
 

  Eye Diseases/Disorders – Clinical Outcomes Studies
PAE5 PREVALENCE OF LOW VISION AND BLINDNESS IN FRANCE
Brézin A1, Lafuma A2, Fagnani F3, Mesbah M4, Berdeaux G5, 1Hopital COCHIN, Paris, France; 2Cemka, Bourg-La-Reine, France; 3CEMKA, Bourg la Reine, France; 4Université de Bretagne-Sud, Vannes, France; 5Alcon, Rueil-Malmaison, France
PAE6 PREVALENCE AND BURDEN OF BLINDNESS AND LOW VISION IN SUBJECTS LIVING IN INSTITUTIONS: A NATION-WIDE SURVEY
Brézin A1, Lafuma A2, Fagnani F3, Mesbah M4, Berdeaux G5, 1Hopital COCHIN, Paris, France; 2Cemka, Bourg-La-Reine, France; 3CEMKA, Bourg la Reine, France; 4Université de Bretagne-Sud, Vannes, France; 5Alcon, Rueil-Malmaison, France
PAE19 PREVALENCE AND BURDEN OF BLINDNESS, LOW VISION AND VISUAL IMPAIRMENT IN THE COMMUNITY: A NATION-WIDE SURVEY
Brézin A1, Lafuma A2, Fagnani FV, Mesbah M4, Berdeaux G5, 1Hopital COCHIN, Paris, France; 2Cemka, Bourg-La-Reine, France; 3CEMKA, Bourg la Reine, France; 4Université de Bretagne-Sud, VANNES, France; 5Alcon, Rueil-Malmaison, France
PAE7 VISION IMPAIRMENT AS AN INDEPENDENT RISK FACTOR OF INSTITUTIONALIZATION
Brézin A1, Lafuma A2, Fagnani F3, Mesbah M4, Berdeaux G5, 1Hopital COCHIN, Paris, France; 2Cemka, Bourg-La-Reine, France; 3CEMKA, Bourg la Reine, France; 4Université de Bretagne-Sud, Vannes, France; 5Alcon, Rueil-Malmaison, France
PAE8 SCORING OF VISUAL FIELD MEASURED THROUGH HUMPHREY PERIMETRY: PRINCIPAL COMPONENT VARIMAX ROTATION FOLLOWED BY CLUSTERING ANALYSIS
Nordmann J1, Mesbah M2, Berdeaux G3, 1Quinze-Vingts Centre Hospitalier National d'Ophtalmologie, Paris, France; 2Université de Bretagne-Sud, Vannes, France; 3Alcon, Rueil-Malmaison, France
 

  Eye Disorders – Cost Studies
PAE9 COST AND EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE TREATMENT OF GLAUCOMA: AN ANALYSIS CONDUCTED USING THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE
Lafuma A1, Voinet C1, Berdeaux G2, 1Cemka, Bourg-La-Reine, France; 2Alcon, Rueil-Malmaison, France
PAE10 COMPARISON OF THE CLINICAL EFFICACY AND COST-EFFECTIVENESS OF LUMIGAN AND XALATAN IN THE TREATMENT OF GLAUCOMA
Roberts G1, Buchholz P2, Holmstrom S3, Finck K3, Gillard S4, Warner J4, Teale C1, 1Allergan Ltd, Buckinghamshire, United Kingdom; 2Allergan, Ettlingen, Germany; 3Allergan, Mougins, France; 4ABACUS International, Oxfordshire, United Kingdom
PAE11 ECONOMIC EVALUATION OF LATANOPROST AS FIRST LINE GLAUCOMA THERAPY IN 6 EUROPEAN COUNTRIES
Aballéa S1, Martin M2, Bernard LV, Althin R4, 1Innovus Research UK, High Wycombe, United Kingdom; 2Innovus Research, High Wycombe, United Kingdom; 3Innovus Research Inc, Burlington, ON, Canada; 4Pfizer, High Wycombe, United Kingdom
PAE12 TREATMENT DURATION AS A COST DRIVER OF GLAUCOMA CARE: A LIFE-LONG SOCIETAL PERSPECTIVE IN FRANCE, GERMANY AND THE NETHERLAND
Lafuma A1, Voinet C1, Berdeaux G2, 1Cemka, Bourg-La-Reine, France; 2Alcon, Rueil-Malmaison, France
PAE13 COST-EFFECTIVENESS ANALYSIS OF TIMOLOL LATANOPROST AND TRAVOPROST IN 3 EUROPEAN COUNTRIES: THE UK, GERMANY AND FRANCE
Lilliu H1, Ligier M1, Le Pen C1, Berdeaux G2, 1Clp-santé, Paris, France; 2Alcon, Rueil-Malmaison, France
PAE14 COST-EFFECTIVENESS ANALYSIS OF PMMA, SILICONE, AND ACRYLIC INTRA-OCULAR LENSES IN CATARACT THERAPY IN FOUR EUROPEAN COUNTRIES
Smith AF1, Lafuma A2, Berto P3, Magaz S4, Berdeaux G5, Auffarth G6, Brézin A7, Caporossi A8, Mendicute J9, Brueggenjuergen B10, 1Alcon Laboratories Ltd and Nuffield Laboratory of Ophthalmology, University of Oxford, Hemel Hempstead, Hertfordshire, United Kingdom; 2CEMKA, Bourg la Reine, France; 3PBE Consulting, Verona, Italy; 4Health Outcomes Policy and Economics, Barcelona, Spain; 5Alcon, Rueil-Malmaison, France; 6Ruprecht-Karls-Universitat, Heidelberg, Heidelberg, Germany; 7Hopital Cochin, Paris, France; 8Universita di Siena, Sienna, Italy; 9Hospital Donostia, Donostia San Sebastain, San Sebastain, Spain; 10Alphacare, Celle, Germany
PAE15 A MULTI-CENTER RETROSPECTIVE STUDY OF RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH GLAUCOMA MANAGEMENT IN FRANCE AND SWEDEN
Orme M1, Curry A1, Buchholz P2, Walt J3, Groleau D4, Holmstrom S5, 1Quintiles UK Ltd, Berkshire, United Kingdom; 2Allergan, Ettlingen, Germany; 3Allergan, Irvine, CA, USA; 4Allergan UK Ltd, Oxford, United Kingdom; 5Allergan, Mougins, France
 

  Eye Disorders - Quality of Life Studies
PAE16 PSYCHOMETRIC VALIDATION OF THE NEI-VFQ 25 FRENCH VERSION IN A POPULATION OF PATIENTS TREATED FOR OCULAR HYPERTENSION AND GLAUCOMA
Nordmann J1, Sullivan K2, Viala M2, Arnould B3, Berdeaux G4, 1Quinze-Vingts Centre Hospitalier National d'Ophtalmologie, Paris, France; 2Mapi Values, Lyon, Rhone, France; 3Mapi Values, Lyon, France; 4Alcon, Rueil-Malmaison, France
PAE17 ASSESSING THE VALUE OF LASER IN SITU KERATOMILEUSIS (LASIK) BY PATIENT REPORTED OUTCOMES
Kang HY1, Cho WH1, Lee JH2, Lee JM2, Park KH2, 1Yonsei University, Seoul, South Korea; 2Chungdam Balgeunsesang Eye Clinic, Seoul, South Korea
PAE18 IMPROVEMENT IN VISION TARGETED QUALITY OF LIFE (QOL) AFTER CATARACT SURGERY WITH IMPLANTATION OF ACRYSOF® NATURAL INTRAOCULAR LENS (IOL)
Venkataraman K, Barnes R, Alcon Labs, Fort Worth, TX, USA
 

   
CARDIOVASCULAR DISEASES/DISORDERS
  Cardiovascular Disease – Clinical Outcomes Studies
PCV1 PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION, ELEVATED TROPONIN T LEVELS AND DIABETES MELLITUS. OUTCOME AT THREE MONTHS
Salvador A, Sevilla B, Roldán I, Baello P, Salim M, Peláez A, Vaquerizo B, Aguar P, Tuzón MT, Mora V, Romero JE, Dr. Peset Hospital, Valencia, Spain
PCV2 NEW TECHNOLOGIES IN THE US MEDICARE: AN EXAMINATION OF STENT ADOPTION
Linde-Zwirble WT1, Ball D2, Copper LM2, 1Health Process Management, Doylestown, PA, USA; 2Eli Lilly and Co, Indianapolis, IN, USA
PCV3 EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PRIMARY CARE IN FRANCE
Van Ganse E1, Moulin P2, Bertrand M3, Souchet T4, Pietri G1, Yin D5, de Pouvourville G6, 1Lyon Sud Hospital, Lyon, France; 2Louis Pradel Hospital, Lyon, France; 3Lille University Hospital, Lambersart, France; 4Merck Sharp & Dohme - Chibret, Paris, France; 5Merck & Co, Whitehouse, NJ, USA; 6INSERM U 537, Le Kremlin-Bicêtre, France
PCV4 PREVENTION OF DEEP-VEIN THROMBOSIS AFTER TOTAL KNEE ARTHROPLASTY IN ASIAN PATIENTS: COMPARISON OF PROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN AND INDOMETHACIN
Wang CJ, Chang Gung Memorial Hospital At Kaosiung, Taiwan
PCV5 OUTCOME AND PROGNOSTIC VALUE OF TROPONIN T IN PATIENTS WITH UNSTABLE ANGINA OR NON-Q-WAVE MYOCARDIAL INFARCTION
Peláez A, Roldán I, Sevilla B, Baello P, Salim M, Tuzón MT, Mora V, Vaquerizo B, Martínez-Diago V, Aguar P, Orriach MD, Salvador A, Dr. Peset Hospital, Valencia, Valencia, Spain
PCV6  ASSESSMENT OF THE QUALITY OF DRUG TREATMENT IN ESSENTIAL HYPERTENSION IN SLOVAK REPUBLIC
Szalayova A, Dubrava M, Kriska M, Comenius University, Bratislava, Slovak Republic
PCV7 MITRAL REPAIR CAN BE SAFELY PERFORMED IN CASES OF INCREASED COMPLEXITY
Sonnad SS1, Badhwar V2, Smolens IA2, Bolling SF2, 1University of Pennsylvania, Philadelphia, PA, USA; 2University of Michigan, Ann Arbor, MI, USA
PCV8 CHOICE OF FIRST-LINE TREATMENT FOR HYPERTENSION IN THE UK: DOES CURRENT PRIMARY CARE PRACTICE REFLECT BRITISH GUIDELINES?
Duerden MG1, Allinson MD1, Thompson M2, 1Keele University, Keele, Staffordshire, United Kingdom; 2IMS Health, Pinner, Middlesex, United Kingdom
 

PCV9 THE USE OF SHORT MESSAGES TO THE PATIENT'S MOBILE PHONE AS HEALTH CARE TOOL IN HYPERTENSION: THE HTA-ALERT STUDY AND THE INFONET PROGRAM
Figueras M1, De la Figuera M2, Márquez E3, Ruilope LM4, Segura J4, Ylla-Català A1, Galera J1, Balañá M1, Naval J5, The HTA-Alert Study Group 16, The INFONET Study Group 17, 1Novartis Farmacéutica, S.A, Barcelona, Spain; 2ABS La Mina. Grupo Cumplimiento Sehlelha, Sant Adrià del Besòs. Barcelona, Spain; 3C.S. La Orden. Grupo Cumplimiento Sehlelha, Huelva, Spain; 4Hospital 12 de Octubre. Sehlelha, Madrid, Spain; 5Infociencia, S.L, Barcelona, Spain; 6The HTA-Alert Study Group, Barcelona, Spain; 7The INFONET Study Group, Barcelona, Spain
PCV10 IMPROVED COMPLIANCE AND PERSISTENCE WITH ATORVASTATINE THROUGH A PHARMACY-BASED INTERVENTION.
de Klerk E, AARDEX Ltd, Maastricht, The Netherlands
PCV11 PREDICTIVE VALUE OF TROPONIN T LEVELS FOR HEART FAILURE AFTER UNSTABLE ANGINA OR NON ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Tuzón MT, Baello P, Sevilla B, Roldán I, Peláez A, Vaquerizo B, Aguar P, Salim M, Montagud V, Almela M, Rincón de Arellano A, Salvador A, Dr. Peset Hospital, Valencia, Valencia, Spain
PCV12 EFFECT OF EPROSARTAN ON PULSE PRESSURE PREDICTIVE FACTORS OF RESPONSE
de la Sierra A1, Arcos E2, Muñoz A3, Relats J3, López JS2, 1Hypertension Unit. Hospital Clínic (Barcelona), Barcelona, Spain; 2Pharma-Consult, Barcelona, Spain; 3Solvay Pharma, Barcelona, Spain
PCV13 A SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES COMPARING READMISSION RATES AND MORTALITY IN PATIENTS WITH HEART FAILURE
Gwadry-Sridhar F, Flintoft V, McMaster University, London, ON, Canada
PCV14 EFFECTIVENESS OF SELF-MEASUREMENT OF BLOOD PRESSURE IN HYPERTENSIVE PATIENTS. DIOAMPA STUDY
Figueras M1, Dalfó A2, Capillas R3, Guash MM4, Ylla-Català A1, Gallardo I1, Balañá M1, Cobos A5, Vidal JM4, 1Novartis Farmaceutica S.A, Barcelona, Spain; 2Equipo de Atención Primária Gòtic, Barcelona, Spain; 3ABS Sant Josep, L'Hospitalet, Barcelona, Spain; 4ABS-"D Universitat, Barcelona, Spain; 5Redes, S.L, Barcelona, Spain
PCV14 EFFECTIVENESS OF SELF-MEASUREMENT OF BLOOD PRESSURE IN HYPERTENSIVE PATIENTS.DIOAMPA STUDY
Figueras M1, Dalfó A2, Capillas R3, Guash MM4, Ylla-Català A1, Gallardo I1, Balañá M1, Cobos A5, Vidal JM4, 1Novartis Farmaceutica S.A,Barcelona,Spain; 2Equipo de Atención Primária Gòtic,Barcelona, Spain; 3ABS Sant Josep, L'Hospitalet, Barcelona, Spain; 4ABS-"D Universitat, Barcelona, Spain; 5Redes, S.L,Barcelona, Spain
PCV15 LOW GOAL ATTAINMENT IN COMMON DAILY PRACTICE AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE NETHERLANDS: THE REALITY-PHARMO STUDY
Goettsch WG1, Yin DD2, Alemao E2, Klungel OH3, Stalenhoef AF4, Herings RMC1, 1PHARMO Institute, Utrecht, The Netherlands; 2Merck & Co., Inc, Whitehouse Station, NJ, USA; 3Utrecht University, Utrecht, The Netherlands; 4University Medical Centre, Nijmegen, The Netherlands
 

  Cardiovascular Disease – Cost Studies
PCV16 EFFECTIVENESS AND COST-EFFECTIVENESS OF THE AMBULATORY BLOOD PRESSURE MONITORING (ABPM) IN THE DIAGNOSTIC OF HYPERTENSION
Rebollo P1, Marin R2, Ortega F1, Valdés C1, Ortega T3, Alvarez-Grande J2, 1Hospital Universitario Central de Asturias and Institute "Reina Sofía" for Nephrological Research, Oviedo, Asturias, Spain; 2Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; 3Hospital Central de Asturias and Institute "Reina Sofia" for Nephrological Research, Oviedo, Asturias, Spain
PCV17 COST-EFFECTIVENESS ANALYSIS OF DALTEPARIN IN PROLONGED PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS AFTER HIP ARTHROPLASTY
Segú JL1, Soto J2, 1CAP la Barceloneta, Barcelona, Spain; 2Pfizer, S.A, Alcobendas, Madrid, Spain
PCV18 HEALTH SYSTEM COSTS OF OUT-OF-HOSPITAL CARDIAC ARREST IN RELATION TO TIME TO SHOCK
Van Alem AP, Dijkgraaf MGW, Koster RW, Academic Medical Center / University of Amsterdam, Amsterdam, The Netherlands
PCV19 A PROBABILISTIC MODEL TO ASSESS THE COST-EFFECTIVENESS OF A NEW STATIN (ROSUVASTATIN) IN THE UK
Palmer S1, Brady AJ2, Ratcliffe A3, 1University of York, York, North Yorkshire, United Kingdom; 2Glasgow Royal Infirmary, Glasgow, United Kingdom; 3AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom
PCV20 ECONOMIC MODELLING OF ANTIPLATELET THERAPY IN THE PREVENTION OF RECURRENT STROKE
Beard S1, Gaffney L1, Bamber L2, 1RTI Health Solutions, Manchester, United Kingdom; 2Boehringer Ingelheim Limited, Bracknell, United Kingdom
PCV21 THE COST OF STROKE IN SWEDEN – AN INCIDENCE ESTIMATE
Ghatnekar O1, Persson U1, Glader EL2, Terént A3, 1IHE, Lund, Sweden; 2Umea University Hospital, Umea, Norrland, Sweden; 3Uppsala University Hospital, Uppsala, Sweden
 

PCV21 THE COST OF STROKE IN SWEDEN – AN INCIDENCE ESTIMATE
Ghatnekar O1, Persson U1, Glader EL2, Terént A3, 1IHE,Lund,Sweden; 2Umea University Hospital,Umea, Norrland,Sweden; 3Uppsala University Hospital,Uppsala, Sweden
PCV22 ECONOMIC EVALUATION OF FONDAPARINUX COMPARED TO ENOXAPARIN IN VENOUS THROMBOEMBOLISM PREVENTION FOLLOWING HIP FRACTURE SURGERY
Gordois A1, Minjoulat-Rey MC2, Carita P2, Gabriel S2, Posnett J2, 1University of York, York, United Kingdom; 2Sanofi Synthelabo Recherche, Bagneux, France
PCV23 ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST- SEGMENT ELEVATION (ACS) UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI): A EUROPEAN OVERVIEW
Spiesser J1, Carita P1, Annemans L2, Lüscher T3, Schwarz B4, Gabriel S5, 1Sanofi-Synthelabo Recherche, Bagneux, France; 2Ghent University, HEDM, Meise, Belgium; 3University Hospital Zurich, Zurich, Switzerland; 4University Vienna, Vienna, Austria; 5Sanofi Synthelabo, Bagneux, France
PCV24 THE MAHLER STUDY: DIFFERENCES IN RESOURCE USE FOR THE MANAGEMENT OF CHRONIC HEART FAILURE ACROSS 6 EUROPEAN COUNTRIES
Lilliu H1, Le Pen C1, Lapuerta P2, Gonzalez-Juanatey J3, Van Veldhuisen D4, Erdmann E5, Poole-Wilson P6, Tavazzi L7, Hermans N8, Priol G1, Komajda M9, 1Clp-santé, Paris, France; 2Bristol-Myers Squibb, Princeton, NJ, USA; 3Hospital Clinico Universitario, Santiago de Compostela, Spain; 4University Hospital, Groningen, The Netherlands; 5University of Köln, Köln, Germany; 6National Heart and Lung Institute, London, United Kingdom; 7IRCCS Policlinico S. Matteo, Pavia, Italy; 8Bristol-Myers Squibb, Waterloo, Belgium; 9Centre Hospitalier Pitié-Salpetrière, Paris, France
PCV25 THE COST AND THE MANAGEMENT OF THE ACUTE PHASE OF MYOCARDIAL INFARCTION AND STROKE IN HUNGARY
Borsos K1, Nagy J2, Belicza E2, Blaskó G1, Spiesser J3, 1Sanofi-Synthelabo Hungary, Budapest, Hungary; 2Egészségügy-kutató Intézet, Budapest, Hungary; 3Sanofi-Synthelabo Recherche, Bagneux, France
 

PCV26  COST-EFFECTIVENESS OF EXTENDING PROPHYLAXIS WITH FONDAPARINUX IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING HIP FRACTURE SURGERY
van HOUT BA1, Minjoulat-Rey MC2, Quinlan D3, Theeuwes A4, Gabriel S2, 1University of Utrecht, Utrecht, The Netherlands; 2Sanofi Synthelabo Recherche, Bagneux, France; 3King's College Hospital, London, United Kingdom; 4Organon, Oos, The Netherlands
PCV27 COST-EFFECTIVENESS ANALYSIS OF ANTITHROMBOTIC TREATMENT WITH CLOPIDOGREL IN PATIENTS WITH MYOCARDIAL INFARCTION, STROKE, AND PERIPHERAL ARTERIAL DISEASE IN THE NETHERLANDS
van Hout BA1, Tangelder MJD2, Bervoets P3, Gabriel S4, 1Pharmerit, Capelle aan de IJssel, The Netherlands; 2Sanofi-Synthelabo, Maassluis, The Netherlands; 3Bristol-Myers Squibb, Woerden, The Netherlands; 4Sanofi Synthelabo, Bagneux, France
PCV28 ECONOMIC EVALUATION AND SURVIVAL ANALYSIS OF IMMUNO-ADSORPTION IN PATIENTS WITH DILATED CARDIOMYOPATHY
Hessel FP1, Wegner C2, Mueller J3, Wasem J1, 1University Duisburg-Essen, Essen, Germany; 2University of Greifswald, Greifswald, Germany; 3German Heart Centre Berlin, Berlin, Germany
PCV29 USE OF RESOURCES AND COST IMPLICATIONS OF STROKE PROPHYLAXIS WITH WARFARIN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Abdelhafiz AH, Wheeldon N, Sheffield University, Sheffield, United Kingdom
PCV30 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN GREEK PATIENTS WITH HYPERLIPIDAEMIA
Papageorgiou M1, Karokis A1, Plumb J2, Ratcliffe A2, Southworth H3, 1AstraZeneca SA, Athens, Greece; 2AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom; 3AstraZeneca R&D, Macclesfield, Cheshire, United Kingdom
PCV31 ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ATHEROTHROMBOTIC EVENTS IN HUNGARY
Borsos K1, Nagy J2, Belicza E2, Spiesser J3, Gabriel S4, Blasko G1, 1Sanofi-Synthelabo Hungary, Budapest, Hungary; 2Egészségügy-kutató Intézet, Budapest, Hungary; 3Sanofi-Synthelabo Recherche, Bagneux, France; 4Sanofi Synthelabo, Bagneux, France
 

PCV32 COSTS OF HOSPITALIZATION IN DEPARTMENT OF CARDIOLOGY FOR PATIENTS WITH SYSTOLIC HEART FAILURE IN FRANCE
Brunot A1, Lenne X1, Dervaux B1, Vincent C2, Degroote P3, 1CRESGE - Université Catholique de Lille, Lille, France; 2Orion Pharma France, Levallois Perret, France; 3Centre Hospito-Universitaire de Lille, Lille, France
PCV33 THE COST-EFFECTIVENESS OF TARKA IN THE TREATMENT OF HEART FAILURE AFTER MYOCARDIAL INFARCTION IN THE US HEALTH CARE SETTING
Nuijten M1, Wittenberg W2, Engelfriet P3, Engelfriet P3, 1MEDTAP International, Jisp, The Netherlands; 2ABBOTT GmbH &Co KG, Ludwigshafen, Germany; 3MEDTAP International Inc, Utrecht, The Netherlands
PCV34 COST-EFFECTIVENESS OF FRACTIONAL FLOW RESERVE TESTING TO GUIDE PERCUTANEOUS CORONARY INTERVENTION IN THE DRUG-ELUTING STENT ERA: A DECISION ANALYSIS
Siebert U1, Greenberg D1, Kuntz KM2, Cohen DJ1, 1Harvard University, Boston, MA, USA; 2Harvard School of Public Health, Boston, MA, USA
PCV35 BURDEN OF HYPERCHOLESTEROLEMIA IN GERMANY
Upmeier H1, Mueller-Nordhorn J1, Englert H1, Sonntag F2, Voeller H3, Wegscheider K4, Windler E4, Meyer-Sabellek W5, Katus HA6, Willich SN1, 1Institute of Social Medicine, Epidemiology and Health Economics, Charité Hospital, Humboldt University of Berlin, Berlin, Germany; 2Cardiologist, Henstedt-Ulzburg, Germany; 3Rehabilitation Center for Cardiovascular Diseases, Rüdersdorf, Germany; 4University of Hamburg, Hamburg, Germany; 5AstraZeneca GmbH, Wedel, Germany; 6University of Heidelberg, Heidelberg, Germany
PCV36 COST-EFFECTIVENESS OF EARLY THROMBOLYSIS FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW OF THE LITERATURE
Boland A, Haycox A, Mujita Mota R, Dundar Y, Bagust A, Dickson R, Walley T, University of Liverpool, Liverpool, United Kingdom
PCV37 THE ADDITIONAL TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE WITH METOPROLOL CR/XL WILL LEAD TO COST SAVINGS IN THE GERMAN HEALTH CARE SYSTEM
Pirk O1, Schoeffski O2, 1Fricke & Pirk GmbH, Nuremberg, Germany; 2University Erlangen-Nuremberg, Nuremberg, Germany
 

PCV38 COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK PATIENTS: AN ECONOMIC EVALUATION BASED ON THE HEART PROTECTION STUDY
Fagnani F1, Lafuma A1, Souchet T2, 1CEMKA, Bourg la Reine, France; 2Merck Sharp & Dohme - Chibret, Paris, France
PCV39 ECONOMIC EVALUATION OF THE MEDENOX (PROPHYLAXIS IN MEDICAL PATIENTS WITH ENOXAPARIN) TRIAL FROM THE PERSPECTIVE OF HOSPITALS IN GERMANY: RESULTS OF A SUBGROUP ANALYSIS
Schädlich PK1, Kentsch M2, Weber M3, Kämmerer W4, Nadipelli V5, Huppertz E6, Brecht JG1, 1InForMed GmbH - Outcomes Research & Health Economics, Ingolstadt, Bavaria, Germany; 2Clinics of Itzehoe, Itzehoe, SH, Germany; 3Clinics of the City of Cologne, Cologne-Merheim, NRW, Germany; 4Dr-Horst-Schmidt-Clinics, Wiesbaden, Hesse, Germany; 5Aventis Pharmaceuticals, Bridgewater, NJ, USA; 6Aventis Pharma Deutschland, Bad Soden am Taunus, Hesse, Germany
PCV40 ASSESSMENT OF THE COST OF CARDIOVASCULAR DEATH
Lamotte M1, Caekelbergh K2, Annemans L3, De Keyser P4, 1Health Economics Disease Management (HEDM), Meise, Belgium; 2HEDM, Meise, Belgium; 3Ghent University, HEDM, Meise, NA, Belgium; 4Solvay Pharma, Brussels, NA, Belgium
PCV41 A COST ANALYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES USING CLOPIDOGREL IN ADDITION TO ASPIRIN IN A HONG KONG PUBLIC HOSPITAL
Lee VW1, Chan WK2, Lau WH1, Lee KK1, 1The Chinese University of Hong Kong, Shatin, Hong Kong, China; 2United Christian Hospital, Kwun Tong, Hong Kong, China
PCV42 ECONOMIC ANALYSIS OF THE USE OF CONTRAST MEDIA DURING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE AND SPAIN
Danchin N1, Macaya C2, Tao WY3, 1HEGP Hospital, Paris, France; 2Hospital University San Carlos, Madrid, Spain; 3The Lewin Group, Hoofddorp, The Netherlands
PCV43 AN EVALUATION OF THE COSTS ASSOCIATED WITH ACUTE MI TREATMENT IN AND OUT OF HOSPITALS IN GREECE
Maniadakis N1, Fragoulakis B2, Liapis M3, Hatzikou M4, 1University of Patras, Patras, Greece; 2University Hospital Patras, Patras, Greece; 3Boehringer Ingelheim, Athens, Greece; 4Boehringer Ingelheim, Athens, Greece
 

PCV44 PHARMACOECONOMIC EVALUATION OF VASOTEC® IN HYPERTENSIVE PATIENTS WITH CONGESTIVE HEART FAILURE : AN UPDATE OF THE RETROSPECTIVE CANADIAN ANALYSIS BASED ON THE STUDIES OF LEFT VENTRICULAR DYSFUNCTION (SOLVD)
Desjardins B1, Marceau C1, Cook JR2, Glick HA3, 1Merck Frosst Canada Ltd, Kirkland, QC, Canada; 2Merck and Co, Blue Bell, PA, USA; 3University of Pennsylvania, Philadelphia, PA, USA
PCV45 LONG-TERM COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY COMPARED TO FIBRINOLYSIS IN ACUTE MYOCARDIAL INFARCTION
Sridhar K, Mahon JL, University of Western Ontario, London, ON, Canada
PCV46 SWITCHING PATIENTS TO ROSUVASTATIN FROM ATORVASTATIN OR OTHER STATINS IS COST-EFFECTIVE: PHARMACOECONOMIC ANALYSIS OF MERCURY I
James M1, Brown J2, Schuster H3, 1AstraZeneca UK Ltd, Macclesfield, Cheshire, United Kingdom; 2AstraZeneca, Macclesfield, Cheshire, United Kingdom; 3INFOGEN Medizinische Genetik GmbH, Berlin, Germany
PCV47 A COST-EFFECTIVENESS ANALYSIS OF TAXUSTM DRUG-ELUTING STENT IN THE UK
Wenk-Lang A1, Knight C2, 1Boston Scientific International, La Garenne Colombes, France; 2Heron Evidence Development Ltd, Letchworth, United Kingdom
PCV48 LONG-TERM COST-EFFECTIVENESS OF INVASIVE STRATEGY IN PATIENT WITH UNSTABLE CORONARY ARTERY DISEASE - RESULTS FROM THE FRISC-II TRIAL
Levin LÅ1, Janzon M2, Swahn E2, 1Center for Medical Technology Assessment CMT, Linköping, Sweden; 2Linköping Universitet, Linköping, Sweden
PCV49 COST-EFFECTIVENESS ANALYSIS OF CITICOLINE VS CONVENTIONAL TREATMENT IN STROKE PATIENTS
Casado A1, Lozano R2, Ibarz R1, Herdman M1, 13D Health Research, Barcelona, Spain; 2Grupo Ferrer S.A, Barcelona, Spain
PCV50 COSTS OF THE DIAGNOSIS OF RENAL ARTERY STENOSIS
van Helvoort-Postulart D1, Dirksen CD1, van Engelshoven JM1, Hunink MG2, 1University Hospital Maastricht, Maastricht, Limburg, The Netherlands; 2Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
PCV51 IRBESARTAN IS COST-SAVING COMPARED TO AMLODIPINE AND STANDARD BLOOD PRESSURE TREATMENT IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN HUNGARY
Palmer AJ1, Borsos K2, Roze S3, Annemans L4, Lamotte M5, Rodby R6, Valentine WJ3, 1CORE Center for Outcomes Research, Basel, BS, Switzerland; 2Sanofi-Synthelabo Hungary, Budapest, Hungary; 3CORE Center for Outcomes Research, Basel, Switzerland; 4University of Ghent, Meise, Belgium; 5Ghent University, Meise, Belgium;
6Rush Presbyterian/St. Luke's Medical Center, Chicago, IL, USA
 

PCV52 ECONOMIC ANALYSIS OF THE USE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION (ACS) FROM THE RUSSIAN HEALTH CARE SYSTEM PERSPECTIVE
Belousov YB1, Lazebnik LB1, Bykov AV2, Nguyen T3, Spiesser J4, 1Russian State Medical University, Moscow, Russia; 2Russian Society for Pharmacoeconomics Research, Moscow, Russia, Moscow, Russia; 3Sanofi-Synthelabo Groupe, Gentilly, France; 4Sanofi-Synthelabo Recherche, Bagneux, France
PCV53 MANAGEMENT OF THE PRIMARY CARE HYPERCHOLESTEROLEMIC PATIENTS THROUGH A CLINICAL DECISION SUPPORT SYSTEM. OPTIMCARE STUDY REPORT
Gambus G1, Bassa A2, Del Val M2, Cobos A3, Torremade E1, Bergonon S3, Crespo C4, Brosa M4, Munio S5, Espinosa C1, 1Novartis Farmacéutica S.A, Barcelona, Spain; 2Vila Olimpica Primary Health Care Center, Barcelona, Spain; 3Rdes, Barcelona, Spain; 4GOC Networking, Barcelona, Spain; 5Laboratorios Geminis S.A, Barcelona, Spain
PCV54 ECONOMIC EVALUATION OF ROSUVASTATIN IN A NATURALISTIC SETTING
Jansen JP1, Goettsch WG2, van Loon J1, Herings RM2, 1Mapi Values, Houten, The Netherlands; 2PHARMO Institute, Utrecht, The Netherlands
PCV55 "FAST-TRACKING" IN THE CARDIAC INTENSIVE CARE UNIT: A TRIAL-BASED ECONOMIC EVALUATION OF THREE SEDATION/ANALGESIA PROTOCOLS IN THE MANAGEMENT OF PATIENTS FOLLOWING CARDIAC SURGERY
Long KH, Oliver Jr WC, Mc Murtry EK, Abel M, Nuttall G, Orszulak TA, Schaff HV, Schroeder DR, Ereth MH, Mayo Clinic, Rochester, MN, USA
PCV56 ESTABLISHING THE COST-EFFECTIVENESS OF STATINS IN THE PRIMARY PREVENTION OF CHD USING A QUASI MARKOV MODEL
Dewilde S, Davies A, Hutton J, MEDTAP International, London, United Kingdom
PCV57 COST EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY IN DIABETIC PATIENTS IN ITALY
Mantovani LG1, Bustacchini S2, Ruffo P2, 1University of Milan, Milan, Italy; 2Pfizer Italia S.r.l, Rome, Italy
PCV58 ECONOMIC IMPACT OF SELECTED FIXED-COMBINATION ANGIOTENSIN-CONVERTING ENZYME INHIBITOR/CALCIUM CHANNEL BLOCKER ANTI-HYPERTENSIVES AMONG PATIENTS WITH DIABETES
Joyce AT, Pedan A, Girase PS, Rucker MB, Ollendorf D, PharMetrics Inc, Watertown, MA, USA
 

PCV59 ECONOMIC EVALUATION OF LOSARTAN COMPARED WITH ATENOLOL IN THE TREATMENT OF HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY: COST-MINIMIZATION ANALYSIS BASED ON LIFE STUDY
Chevreul K1, Durand-zaleski I2, Souchet T3, 1Robert Debré Hospital, Paris, France; 2Henri Mondor Hospital, Créteil, France; 3Merck Sharp & Dohme - Chibret, France, Paris, France
PCV60 INTRODUCTION OF ROSUVASTATIN WILL ENABLE MORE PATIENTS TO ACHIEVE GUIDELINE LDL-C GOALS WITHIN A FIXED BUDGET IN THE UK
Ryan J1, Gilmour R2, Piercy J3, Saleh A4, Brown J5, 1Mapi Values, Macclesfield, United Kingdom; 2Adelphi Medi Cine, London, United Kingdom; 3Adelphi Group, Macclesfield, Cheshire, United Kingdom; 4Mapi Values, Macclesfield, Cheshire, United Kingdom; 5AstraZeneca, Macclesfield, Cheshire, United Kingdom
PCV61 THE COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS WITH ENOXAPARIN VERSUS SHORT-TERM PROPHYLAXIS AFTER ELECTIVE HIP REPLACEMENT IN POLAND
Orlewska E, Medical University of Warsaw, Warsaw, Poland
PCV62 CLINICAL AND ECONOMIC OUTCOMES OF FONDAPARINUX VS. ENOXAPARIN IN THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY IN SPAIN
Slof J1, Magaz S1, Badia X2, 1Health Outcomes Policy & Economics, Barcelona, Spain; 2Health Outcomes Research Europe Group, Barcelona, Spain
PCV63 COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN THE NETHERLANDS
van Hout BA1, Tangelder MJD2, Bervoets P3, Gabriel S4, 1Pharmerit, Capelle aan de IJssel, The Netherlands; 2Sanofi-Synthelabo, Maassluis, The Netherlands; 3Bristol-Myers Squibb, Woerden, The Netherlands; 4Sanofi Synthelabo, Bagneux, France
PCV64 COST-EFFECTIVENESS ANALYSIS OF CORONARY REVASCULARISATION TECHNIQUES AVAILABLE FOR THE TREATMENT OF ISCHAEMIC HEART DISEASE
Magaz S1, Badia X2, Annemans L3, Lamotte M4, 1Health Outcomes Policy And Economics, Barcelona, Spain; 2Health Outcomes Research Europe Group, Barcelona, Spain; 3Ghent University, HEDM, Meise, Belgium; 4Health Economics Disease Management (HEDM), Meise, Belgium
 

PCV65 EVALUATING THE ECONOMIC VALUE OF SIROLIMUS-ELUTING STENT IN KOREA
Kang HY1, Park EC1, Park KD2, Park JE1, Lee HY1, 1Yonsei University, Seoul, South Korea; 2Seoul National University, Seoul, South Korea
PCV66 ONE BILLION EURO FOR THE TREATMENT WITH CSE-ANTAGONISTS IN GERMANY – WHAT ARE THE RESULTS?
Pirk O1, Raming B2, Schoeffski O3, 1Fricke & Pirk GmbH, Nuremberg, Germany; 2AstraZeneca GmbH, Wedel, Germany; 3University Erlangen-Nuremberg, Nuremberg, Germany
PCV67 AN ECONOMIC EVALUATION OF ALTEPLASE, RETEPLASE AND TENECTEPLASE IN TREATMENT OF ACUTE MI IN GREECE
Maniadakis N1, Hatzikou M2, Kaitelidou D3, Spinthouri M4, Siskou O3, Fragoulakis B5, Liappis T6, Liaropoulos L4, 1University of Patras, Patras, Greece; 2Boehringer Ingelheim, Athens, Greece; 3University of Athens, Athens, Greece; 4University of Athens, Athnes, Greece; 5University Hospital Patras, Patras, Greece; 6Boehringer Ingelheim, Athens, Greece
PCV68 WITHDRAWN
PCV69 THE COST-EFFECTIVENESS OF CYP2C9 GENOTYPING IN MANAGEMENT OF WARFARIN THERAPY - A DECISION TREE ANAYSIS
You JH, Chan FW, Cheng G, The Chinese University of Hong Kong, Hong Kong, China
PCV70 A PHARMACOECONOMIC COMPARISON OF UNFRACTIONATED HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN USAGE IN ACUTE CORONARY SYNDROME IN RUSSIA
Lazebnik LB1, Kuznetsova NA2, Gavrilova AV2, Komarova VP3, 1Russian State Medical University, Moscow, Russia; 2Moscow Health Care Department, Moscow, Russia; 3Aventis Pharma, Moscow, Russia
PCV71 AN ECONOMIC EVALUATION OF TREATMENTS FOR ACUTE MI IN GREECE IN ELDERLY AND LATE TREATMENT PATIENTS
Maniadakis N1, Hatzikou M2, liappis T2, Kaitelidou D3, Spinthouri M4, Siskou O3, Fragoulakis B5, Liaropoulos L4, 1University of Patras, Patras, Greece; 2Boehringer Ingelheim, Athens, Greece; 3University of Athens, Athens, Greece; 4University of Athens, Athnes, Greece; 5University Hospital Patras, Patras, Greece
PCV72 COST-EFFECTIVENESS OF ATORVASTATIN COMPARED TO SIMVASTATIN IN THE NETHERLANDS
Severens JL1, Prins MH2, Monteban HC3, 1University Maastricht, Maastricht, The Netherlands; 2University Hospital Maastricht, Maastricht, The Netherlands; 3Pfizer, Capelle a/d IJssel, The Netherlands
 

  Cardiovascular Disease – Quality of Life Studies
PCV73 DEVELOPMENT OF PATIENT-REPORTED OUTCOME MEASURES FOR PULMONARY ARTERIAL HYPERTENSION
McKenna SP1, Doughty N2, Pepke-Zaba J2, Meads D1, Doward L1, 1Galen Research, Manchester, United Kingdom; 2Papworth Hospital, Cambridge, United Kingdom
PCV74 MEASURING HEALTH RELATED QUALITY OF LIFE AFTER STROKE
Lopez Bastida J1, Serrano Aguilar P1, Monton Alvarez F2, Duque González B1, 1Canarian Health Service, Santa Cruz de Tenerife, S/C de Tenerife, Spain; 2Ntra. Sra. de la Candelaria, Universitary Hospital, Santa Cruz de Tenerife, S/C de Tenerife, Spain
PCV75 PROJECTED LIFE YEAR GAINED AND OTHER BENEFITS OF EZETIMIBE CO-ADMINISTRATION IN CHD PATIENTS NOT ATTAINING TOTAL CHOLESTEROL GOAL WITH STATIN MONOTHERAPY IN FINLAND
Cook J1, Alemao E2, Veltri E3, Yin DD4, 1Merck Research Labs, Blue Bell, PA, USA; 2Merck and Co, Whitehouse Station, NJ, USA; 3Schering Plough Pharmaceutical, Kenilworth, NJ, USA; 4Merck & Co., Inc, Whitehouse Station, NJ, USA
PCV76 IS THE MLHF QUESTIONNAIRE VALID FOR INTERNATIONAL MULTICENTRIC STUDIES?
Garin O1, Ferrer M1, Pont A1, Wiklund I2, Van Ganse E3, Pietri G3, Lobo-Luppi L4, Alonso J1, 1Institut Municipal d'Investigació Mèdica, (IMIM-IMAS), Barcelona, Cataluña, Spain; 2Astra Hässle Research Laboratoris, Möelndal, Sweden; 3Lyon Sud Hospital, Lyon, France; 4for the IQOD group, Mapi Research Institute, Lyon, France
PCV77 THE ECONOMIC ASSESSMENT OF LIPID LOWERING THERAPY WITH EZETIMIBE IN SPAIN
Davies GM1, Cook JR1, Nocea G2, Veltri E3, Alemao E4, Yin DD4, 1Merck Research Labs, Blue Bell, PA, USA; 2Merck Sharp & Dohme, España, Madrid, Spain; 3Schering Plough Pharmaceutical, Kenilworth, NJ, USA; 4Merck & Co., Inc, Whitehouse Station, NJ, USA
PCV78 QUALITY OF LIFE IN CHRONIC PATHOLOGIES IN PRIMARY CARE
Leiva F1, Garcia Ruiz AJ2, Martos Crespo F2, Prados Torres JD1, Sanchez de la Cuesta F2, 1Family Practice Department, Malaga, Spain; 2PharmacoEconomics and Outcomes Research Unit, Malaga, Spain
PCV79  DEVELOPMENT AND VALIDATION OF THE NEW HEALTH-RELATED QUALITY OF LIFE INSTRUMENT SPECIFIC TO PATIENTS WITH CORONARY ARTERY DISEASE (CAD) IN POLAND: POL-CAD
Jaworski R1, Muszynska A2, Halik J3, Harmata W4, Czech M1, Pachocki R1, 1Servier Poland Research Institute, Warsaw, Poland; 2Medical University, Warsaw, Poland; 3Centre for the Informative Systems in Health Care, Warsaw, Poland; 4Military Institute of Chemistry and Radiometry, Warsaw, Poland
PCV80 EARLY EVOLUTION, DETERMINANTS AND PREDICTIVE POWER OF HEALTH RELATED QUALITY OF LIFE IN A MULTICENTRIC POPULATION OF PATIENTS WITH HEART FAILURE
Permanyer-Miralda G, Soriano N,University Hospital Vall d'Hebron, Barcelona, Spain
 

 
DIABETES
  Diabetes – Clinical Outcomes Studies
PDB1  IMPROVED GLYCAEMIC CONTROL AND LESS HYPOGLYCAEMIA WITH INSULIN GLARGINE COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES LEADS TO FEWER LONG-TERM COMPLICATIONS – RESULTS OF THE DIABETES MELLITUS SIMULATION MODEL
Maxion-Bergemann S1, Müller E1, Bergemann R1, Walleser S1, Huppertz E2, 1Institute for Medical Outcome Research (IMOR) GmbH, Lörrach, Germany; 2Aventis Pharma Deutschland GmbH, Bad Soden/Taunus, Germany
PDB2  IS THERE A GAIN WITH THE PAIN? ASSESSMENT OF THE RELATIONSHIP BETWEEN SELF-REPORTED ADHERENCE TO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) AND HBA1C LEVELS AMONG TYPE 2 DIABETICS
Vincze G, Barner JC, Lopez DA, University of Texas at Austin, Austin, TX, USA
PDB3 CLAIMS DATA MEASUREMENTS OF MEDICATION ADHERENCE AND METABOLIC OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES (DM2)
Pladevall M, Loomis LA, Williams K, Xi H, Akkerman N, Elston-Lafata J, Henry Ford Health System, Detroit, MI, USA
PDB4 POPULATION-BASED DIABETES INTERVENTION IN A MANAGED CARE SETTING
Buchner DA1, Ershoff D2, Fazio C3, Mackey AL4, 1Schering-Plough, Kenilworth, NJ, USA; 2Astra Zeneca, Tarzana, CA, USA; 3Medica, Minnetonka, MN, USA; 4BMS, Eden Prairie, MN, USA
PDB5 EVIDENCE-BASED ASSESSMENT OF PATIENTS' RISK AND POTENTIAL REGARDING THE LONG-TERM COMPLICATIONS OF DIABETES USING A NEW MODEL OF PROGNOSIS IN THE DM PROJECT DIAMART
Mast O1, Schumacher A2, Mueller A2, Lickvers K3, Kottmair S3, Derdzinski BF4, Hecke T4, Ziegenhagen DJ4, Frank M5, 1Institute for Medical Informatics and Biostatistics, Basel, Switzerland; 2HESTIA HealthCare GmbH, Mannheim, Germany; 3ArztPartner almeda AG, Munich, Germany; 4Deutsche Krankenversicherung AG, Cologne, Germany; 5Saarlandklinik Kreuznacher Diakonie, Neunkirchen, Germany
PDB6 PREVALENCE OF RENAL FAILURE IN DIABETES TYPE 2: RESULTS FROM A POPULATION STUDY AND THE BELGIAN ESRD REGISTRY
Verpooten GA, Nederlandstalige Belgische Vereniging voor Nefrologie, Universiteit Antwerpen, Edegem, Belgium
PDB7 THE IMPACT ON GLYCEMIC CONTROL OF DIABETIC PATIENTS BY A HOSPITAL PHARMACIST-MANAGED COMPLICANCE CLINIC IN HONG KONG
Lee VW, Leung PY, Lee KK, The Chinese University of Hong Kong, Shatin, Hong Kong, China
PDB8 AN ANALYSIS OF THE RELATIONSHIP BETWEEN RAPID TRANSITION TO INSULIN, AREA UNDER THE CURVE FOR HBA1C MEASURES ACROSS TIME AND DIABETES-RELATED COMPLICATIONS: A GERMANY POPULATION BASED STUDY
Simons WR1, Bolinder B2, Vinod H3, 1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA; 2Aventis Pharmaceuticals, Bridgewater, NJ, USA; 3Fordham University, Summit, NJ, USA
 

  Diabetes – Cost Studies
PDB9 THE COMPACT-STUDY: PIOGLITAZONE VS. INSULIN FOR TREATMENT OF PATIENTS WITH TYPE-2-DIABETES MELLITUS - A MEDICAL AND PHARMACOECONOMIC ANALYSIS
Lübben G1, Fennenkötter U1, Weidenhammer J2, Golbach U2, Kusterer K3, Lundershausen R4, Münscher C5, Potthoff F5, 1TAKEDA PHARMA GMBH, Aachen, Germany; 2Institut für Gesundheits- und Systemforschung GmbH, Kiel, Germany; 3Diabetic Centre Mannheim, Mannheim, Germany; 4Clinic Bergfried Saalfeld, Saalfeld, Germany; 5Medical NetCare GmbH, Münster, Germany
PDB10 DIABETES DISEASE MANAGEMENT IS ASSOCIATED WITH PHARMACY SAVINGS IN A MANAGED CARE SETTING
Sidorov J1, Wolke OF2, Fischer FJ3, 1Geisinger Health Plan, Danville, PA, USA; 2Schellen and Partners Usa, Inc., Danville, PA, USA; 3Schellen and Partner GmbH, Düsseldorf, Germany
PDB11 THE ECONOMIC CONSEQUENCES OF DIABETES TYPE 2 IN POLAND
Niewada MP1, Glogowski CA2, Pietrasik AL1, £atek M3, Kamiñski B3, Gierczynski JM2, Krzyzanowska AM2, 1Medical University of Warsaw, Warsaw, Poland; 2GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland; 3Warsaw School of Economics, Warsaw, Poland
PDB12 TYPE-2 DIABETES AND HOSPITAL COSTS ACCORDING TO OBESITY: A RETROSPECTIVE ANALYSIS FROM A HOSPITAL DATA BASE IN FRANCE
Riveline JP1, Petit C1, Dinet J2, Sevellec C3, Nabarette H3, Dispot T3, Charpentier G1, 1Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France; 2Sanofi-Synthelabo Recherche, Bagneux, France; 3Medcost, Paris, France
PDB13 PREDICTORS OF EMERGENCY DEPARTMENT VISITS IN ELDERLY PATIENTS WITH DIABETES
Chen GJ, Teuschler H, Moran WP, Wake Forest University Health Science, Winston-Salem, NC, USA
PDB14 COST- EFFECTIVENESS ANALYSIS OF THE ACARBOSE PHARMACOLOGICAL TREATMENT AS A PREVENTIVE MEASURE OF THE DEVELOPMENT OF TYPE 2 DIABETES IN SUBJECTS DIAGNOSED OF IMPAIRED GLUCOSE TOLERANCE (IGT)
Sabés R, Universitat Pompeu Fabra, Barcelona, Spain
 

PDB15 RISK OF CONGESTIVE HEART FAILURE IN TYPE 2 DIABETICS EXPOSED TO PIOGLITAZONE VS INSULIN: A MATCHED COHORT ANALYSIS
Rajagopalan R1, Rosenson R2, Murray FT1, 1Takeda Pharmaceuticals North America, Inc, Lincolnshire, IL, USA; 2Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
PDB16 COST-EFFECTIVENESS OF BLOOD PRESSURE AND URINARY ALBUMIN CONTROL IN DIABETICS WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER: PHARMACOECONOMIC ANALYSIS OF THE MARVAL TRIAL – THE CASE OF GERMANY
Smith DG1, Gnanasakthy A2, Quednau K3, 1University of Michigan, Ann Arbor, MI, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Novartis Pharma GmbH, Nuremberg, Germany
PDB17 PREDICTED COSTS AND OUTCOMES FROM REDUCED VIBRATION DETECTION IN PEOPLE WITH DIABETES IN THE UK
Shearer A1, Scuffham P1, Gordois A1, Oglesby A2, 1University of York, York, United Kingdom; 2Eli Lilly & Company, Indianapolis, IN, USA
PDB18 THE COMPLICATIONS IMPACT ON DIABETES TYPE 2 DIRECT COSTS IN POLAND
Niewada MP1, Glogowski CA2, Latek M3, Pietrasik A3, Kamiñski B3, Gierczynski JM2, Krzy¿anowska A2, 1Medical University of Warsaw, Warsaw, Poland; 2GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland; 3Warsaw School of Economics, Warsaw, Poland
PDB19 ADVANCED TOOLS FOR ALLOCATION OF MEDICAL PRODUCTS: ECONOMIC EVALUATION OF THE "HOMECARE" PROGRAMME
de Portu S1, Gradnik PA2, Recchia A2, Munna E2, Mantovani LG3, 1University of Milan, Milan, Italy; 2Associazione Chimica Farmaceutica LOMBARDA fra Titolari di Farmacia, Milan, Italy; 3University of Milan, Milan, Italy
PDB21

 

A COST-UTILITY ANALYSIS OF INSULIN GLARGINE (LANTUS®) IN THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES
Kristensen FK1, Sverre JM1, Bustad S2, 1PharmEcon AS, Asker, Norway; 2Aventis Pharma AS, Lysaker, Norway
 

  Diabetes – Quality of Life Studies
PDB20 THE IMPACT OF DIABETES TYPE 2 ON QUALITY OF LIFE
Niewada MP1, Glogowski CA2, Gierczynski JM2, Latek M3, Pietrasik AL1, Kamiñski B3, Krzyzanowska AM2, 1Medical University of Warsaw, Warsaw, Poland; 2GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland; 3Warsaw School of Economics, Warsaw, Poland
 
GASTROINTESTINAL DISEASES/DISORDERS
  Gastrointestinal Disorders – Clinical Outcomes Studies
PGS1 AN EVIDENCE-BASED APPROACH PROVIDES A QUANTITATIVE ASSESSMENT OF THE EFFICACY OF ESOMEPRAZOLE FOR HEALING OF EROSIVE ESOPHAGITIS BASED ON DISEASE SEVERITY
Johnson DA1, Roach A2, Traxler BM2, Levine D2, 1Eastern Virginia School of Medicine, Norfolk, VA, USA; 2AstraZeneca LP, Wilmington, DE, USA
PGS2 A RETROSPECTIVE AUDIT OF PATIENTS REDUCING PROTON PUMP INHIBITOR DOSE TO LANSOPRAZOLE 15MG
Emmas CE, Rosen JP, AstraZeneca UK, Luton, United Kingdom
PGS3 META-ANALYSIS OF PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI
Edwards SJ, Plumb JM, AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom
PGS4 ESOMEPRAZOLE AS MAINTENANCE THERAPY IN EROSIVE ESOPHAGITIS: A QUANTITATIVE ASSESSMENT OF EFFICACY USING AN EVIDENCE-BASED APPROACH
Johnson DA1, Roach A2, Traxler BM2, Levine D2, Lauritsen K3, 1Eastern Virginia School of Medicine, Norfolk, VA, USA; 2AstraZeneca LP, Wilmington, DE, USA; 3Odense University Hospital, Odense, Denmark
 

  Gastrointestinal Disorders – Cost Studies
PGS5 ECONOMIC BURDEN OF IRRITABLE BOWEL SYNDROME (IBS): ONE YEAR RESULTS. RITMO STUDY
Badia X1, Mearín F2, Caballero A3, Benavent J4, Díaz-Rubio M5, Domínguez E6, Garrigues V7, Vázquez J8, Piqué J9, Figueres M10, Cucala M10, Balañá M10, Roset M1, RITMO Study Group11, 1Health Outcomes Research Europe, Barcelona, Spain; 2Centro Médico Teknon, Barcelona, Spain; 3Granada University. School of Medicine, Granada, Spain; 4Área Básica de Salud de Montigalá, Badalona, Spain; 5Hospital Clínico San Carlos, Madrid, Spain; 6Hospital Clínico Universitario de Galícia, Santiago de Compostela, Spain; 7Hospital de la Fe, Valencia, Spain; 8Clínica del aparato digestivo, A Coruña, Spain; 9Hospital Clínico de Barcelona, Barcelona, Spain; 10Novartis Farmacéutica, Barcelona, Spain; 11Barcelona, Spain
PGS6 COST EFFECTIVENESS OF CONTINUOUS AND ON-DEMAND THERAPY WITH ESOMEPRAZOLE 20 MG IN PATIENTS WITH SYMPTOMATIC GASTROESOPHGEAL REFLUX DISEASE (GERD): THE ONE STUDY
Edouard L1, Urbain D2, Vandenhoven G3, Duquenne V3, 1University Hospital of Liege, Liege, Belgium; 2Free University of Brussels, Jette, Belgium; 3AstraZeneca, Bruxelles, Belgium
PGS7 COST ANALYSIS OF A NEW PROPOSAL FOR REIMBURSEMENT OF PROTON PUMP INHIBITOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN BELGIUM
Van Wilder PB1, Arickx F1, Vannecke C1, Hiele M2, Verpooten GA3, 1RIZIV-INAMI, Brussels, Belgium; 2KU Leuven, Leuven, Belgium; 3University of Antwerpen, Edegem, Belgium
PGS8 COST-MINIMISATION ANALYSIS OF PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI
Plumb JM, Edwards SJ, AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom
PGS9 A COST CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC INJECTABLE TREATMENT VERSUS SURGERY IN PATIENTS WITH SEVERE GASTRO ESOPHAGEAL REFLUX DISEASE IN FRANCE
Lamarsalle L1, Castanier J1, Vainchtock A1, Granger-Pascot M2, 1GYD Institut, Lyon, France; 2Boston Scientific France, St Quentin en Yvelines, France
PGS10 COST OF ILLNESS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN ITALY
Di Stasi F1, Teruzzi C2, Mantovani LG1, 1University of Milan, Milan, Italy; 2Bracco, Milan, Italy
PGS11 USING A COST-UTILITY ANALYSIS FOR ASSESSING SENSITIVITY IN DRUG PRICES OF ESOMEPRAZOLE VERSUS OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX OESOPHAGITIS IN THE UK
Wahlqvist P, AstraZeneca R&D Mölndal, Mölndal, Sweden
PGS12 IMPACT ON WORK PRODUCTIVITY OF UPPER GASTROINTESTINAL SYMPTOMS ASSOCIATED WITH CHRONIC NSAID THERAPY IN A SWEDISH STUDY POPULATION
Wahlqvist P, Bergenheim K, Långström G, Naesdal J, AstraZeneca R&D Mölndal, Mölndal, Sweden
PGS13 COST OF ILLNESS AND QUALITY OF LIFE OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS IN ITALY
Rossetti F, Montovani L, University of Milan, Milan, Italy
PGS14 CROHN´S DISEASE IN SLOVAKIA AND QUALITY OF LIFE
Bielik J, Hlista M, Èernok S, Šorf M
Hospital Nové Mesto nad Váhom, Hospital Trenèín, Slovakia, Slovak Republic
 

 
MENTAL HEALTH
  Mental Health – Clinical Outcomes Studies
PMH1 METHYLPHENIDATE FORMULATION IS ASSOCIATED WITH ACCIDENT/INJURY RATE IN CHILDREN WITH ADHD
Lage M1, Hwang P2, 1HealthMetrics Outcomes Research, Groton, CT, USA; 2Janssen-Ortho Inc, Toronto, ON, Canada
PMH2 EVALUATION OF ANTIDEPRESSANT MEDICATION ADHERENCE IN A NOT FOR PROFIT HEALTH CARE ORGANIZATION
Alison LM1, Wong SL2, Day D3, 1Healthfirst, Inc, New York, NY, USA; 2Pfizer, Inc, Syosset, NY, USA; 3Pfizer, Inc, New York, NY, USA
PMH3 EVALUATION OF MEDICAL DIAGNOSES FOR TEXAS MEDICAID PATIENTS PRESCRIBED ATYPICAL ANTIPSYCHOTIC MEDICATIONS
Harrington PM1, Rascati KL1, Johnsrud M2, 1The University of Texas College of Pharmacy, Austin, TX, USA; 2The Center for Pharmacoeconomic Studies - The University of Texas, Austin, TX, USA
PMH4 2-YEAR OUTCOMES OF RISPERDAL® CONSTA™ - THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC: RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA
Trakas K1, Talling D2, Balshaw R2, Love L2, Robinson K1, 1Janssen-Ortho Inc, Toronto, ON, Canada; 2Syreon Corporation, Vancouver, BC, Canada
PMH5 FUNCTIONING AND HEALTH CARE RESOURCE USE OF SCHIZOPHRENIC PATIENTS IN A ONE-YEAR FOLLOW-UP STUDY. SOHO STUDY
Prieto L1, Escobar R1, Bousoño M2, González-Torres M3, Mayoral F4, Montejo A5, Olivares J6, Ros S7, Sanjuan J8, 1Lilly, S.A, Alcobendas, Madrid, Spain; 2Universidad de Oviedo, Alcobendas, Madrid, Spain; 3Hospital de Basurto, Bilbao, Vizkaia, Spain; 4Complejo Hospitalario Carlos Haya, Málaga, Spain; 5Hospital Universitario de Salamanca, Salamanca, Spain; 6Complejo Hospitalario Xeral-Cies, Vigo, Pontevedra, Spain; 7Hospital del Mar, Barcelona, Spain; 8Universidad de Valencia, Alcobendas, Madrid, Spain
PMH6 PHARMACOUTILIZATION OF ANTIDEPRESSANT DRUGS IN PRIMARY CARE: A LONG-TERM RETROSPECTIVE ANALYSIS OF A LARGE POPULATION
Russo P1, Degli Esposti L2, Baiardi F2, Degli Esposti E3, Carmosino G4, 1University of Rome "La Sapienza", Rome, Italy; 2CliCon Srl, Health Economics and Outcomes Research, Ravenna, Italy; 3Ravenna Local Health Unit, Ravenna, Italy; 4Lundbeck Italy, Milan, Italy
 

  Mental Health – Cost Studies
PMH7 COST EFFECTIVENESS OF PHARMACOLOGICAL TREATMENT VERSUS CARE AS USUAL FOR PANIC DISORDER AND/OR DEPRESSION DRIVEN CHEST PAIN: PRELIMINARY RESULTS OF UNBLINDED DATA
Brunenberg D, Dirksen C, Kuijpers P, Honig A, University Hospital Maastricht, Maastricht, The Netherlands
PMH8 PREVALENCE AND MEDICAL CARE COSTS OF ANXIETY DISORDERS IN THE UNITED STATES: A NATIONAL ESTIMATE USING THE MEDICAL EXPENDITURE PANEL SURVEY
Mychaskiw MA, Sankaranarayanan J, Purdue University, West Lafayette, IN, USA
PMH9  THE SOCIO-ECONOMIC BURDEN OF BIPOLAR DISORDER IN THE NETHERLANDS
Hakkaart L1, Hoeijenbos M1, Regeer EJ2, ten Have M3, Nolen WA4, Veraart C5, Rutten F6, 1Erasmus University Rotterdam, Rotterdam, The Netherlands; 2Altrecht Institute for Mental Health Care, Utrecht, The Netherlands; 3The Netherlands Institute for Mental Health and Addiction, Utrecht, The Netherlands; 4Altrecht Institute for Mental Health Care, Utrecht, The Netherlands; 5Eli Lilly, The Netherlands, Houten, Utrecht, The Netherlands; 6Institute for Medical Technology Assessment, Erasmus Medical Centre, The Netherlands, Rotterdam, Zuid-Holland, The Netherlands
PMH10 COSTS AND EFFECTS OF RISPERDAL CONSTATM IN COMPARISON TO CONVENTIONAL DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN GERMANY
Heeg BM1, Emmermann A2, Laux G3, Möller HJ4, Naber D5, Van Hout BA1, 1PharMerit BV, Capelle a/d IJssel, The Netherlands; 2Janssen-Cilag GmbH, Neuss, Germany; 3Bezirkskrankenhaus Gabersee, Wasserburg, Germany; 4Klinikum der Universität München, München, Germany; 5Universitätskrankenhaus Eppendorf, Hamburg, Germany
PMH11 PRODUCTION LOSSES IN BORDERLINE PERSONALITY DISORDER: SHORTCOMINGS IN THE STANDARD METHODS OF VALUATION
van Asselt ADI1, Dirksen CD1, Severens JL2, Arntz A2, 1University Hospital Maastricht, Maastricht, The Netherlands; 2University Maastricht, Maastricht, The Netherlands
 

PMH12 ECONOMIC CONSEQUENCES OF THE ADVERSE EVENTS RELATED WITH CURRENT ANTIPSYCHOTICS
Bobes J1, Cañas F2, Rejas J3, Expósito I4, Mackell JA5, 1University of Oviedo, Oviedo, Spain; 2Psyquiatric Hospital of Madrid, Madrid, Spain; 3Health Outcomes Research, Medical Unit, Pfizer SA, Alcobendas, Madrid, Spain; 4Health Outcomes Research, Pfizer SA, Alcobendas, Madrid, Spain; 5Pfizer Inc, New York, NY, USA
PMH13 AFFECTIVE PSYCHOSES IN ADOLESCENTS: THE ECONOMIC CONSEQUENCES OF ACUTE CARE HOSPITAL ADMISSIONS OVER THREE YEARS
O'Brien JA, Pitoniak-Morse CA, Caro JJ, Caro Research Institute, Concord, MA, USA
PMH14 THE BURDEN OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD) IN THE NORDIC COUNTRIES - A LITERATURE REVIEW
Närhi V1, Bernfort L2, Heikkinen K3, Myrén K4, 1Niilo Mäki Institute, Jyväskylä, Finland; 2Center for Medical Technology Assessment (CMT), Linköping, Sweden; 3Oy Eli Lilly Finland AB, Vantaa, Finland; 4Eli Lilly Sweden AB, Stockholm, Sweden
PMH15
 
COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE (LA-RIS) VS HALOPERIDOL DECANOATE AND ORAL OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY
D'Ausilio A1, Amaddeo F2, Mencacci C3, Munizza C4, Miadi-Fargier H5, Berto P1, 1PBE consulting, Verona, Italy; 2Ospedale Policlinico "G.B. Rossi", Verona, Italy; 3Azienda Ospedaliera Fatebenefratelli-Oftalmico, Milano, Italy; 4ASL, Torino, Italy; 5A.C.E. Annie Chicoye Economics, Neuilly-sur-Seine, France
PMH16 AN ECONOMIC EVALUATION OF ARIPIPRAZOLE VERSUS OLANZAPINE IN A SWEDISH SETTING USING OUTCOMES OF METABOLIC SYNDROME, PROJECTED DIABETES AND CORONARY HEART DISEASE
Ruppert A1, Waldeck R2, Cislo P2, Pugner K1, Iwamoto T3, Yuan Y4, Ösby U5, 1Bristol-Myers Squibb, Waterloo, Belgium; 2Bristol-Myers Squibb, Wallingford, CT, USA; 3Bristol Myers Squibb, Wallingford, CT, USA; 3Otsuka, Rockville, MD, USA; 4Bristol-Myers Squibb, Princeton, NJ, USA; 5 Karolinska Institute, Stockholm, Sweden
 

  Mental Health – Quality of Life Studies
PMH17 HEALTH-RELATED QUALITY OF LIFE IN OUTPATIENTS WITH SCHIZOPHRENIA IN SINGAPORE
Luo N1, Seng BK2, Li SC1, Thumboo J3, 1National University of Singapore, Singapore; 2Institute of Mental Health, Singapore, Singapore; 3Singapore General Hospital, Singapore, Singapore
PMH18 ZIPRASIDONE VS OLANZAPINE: CHANGE IN CHD RISK DURING A SIX-WEEK TRIAL
Mackell JA, Leaderer MC, Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA
PMH19 CLIENT AND STAFF INVOLVEMENT IN FORMAT DESIGN OF A HEALTH-RELATED QUALITY OF LIFE SURVEY FOR INDIVIDUALS WITH SCHIZOPHRENIA, THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP) SURVEY
Barr JT, Schumacher GE, Ohman SM, Quimby CM, Northeastern University, Boston, MA, USA
PMH20 TREATMENT WITH PSYCHOSTIMULANTS IS ASSOCIATED WITH DECREASED RATES OF SUBSTANCE ABUSE AND IMPROVED SCHOOL OUTCOMES AMONG CHILDREN WITH AD/HD
Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Mrazek DA, Jacobsen SJ, Mayo Clinic, Rochester, MN, USA
PMH21 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY: SPANISH RESULTS
Taïeb C1, Garrido JA2, Myon E1, 1Pharmaco Economics & Quality of Life Department, Boulogne Billancourt, France; 2Pierre Fabre Iberica, Barcelona, Spain
PMH22 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY: ITALIAN RESULTS
Taïeb C1, Garrido JA2, Myon E1, 1Pharmaco Economics & Quality of Life Department, Boulogne Billancourt, France; 2Pierre Fabre Iberica, Barcelona, Spain
 

PMH24 EARLY SUSTAINED REMISSION IN PATIENT-REPORTED OUTCOMES AMONG PRIMARY CARE PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Sapin C1, Fantino B2, François C3, 1Altipharm, Paris, France; 2ADIM-AGORAS, Lyon, France; 3H. Lundbeck A/S, Paris, France
PMH25 ASSESSING HEALTH-RELATED QUALITY OF LIFE IN CLINICAL TRIALS OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Sapin C1, Le Lay A2, Llorca PM3, François C2, 1Altipharm, Paris, France; 2H. Lundbeck A/S, Paris, France; 3CH Sainte-Marie, Clermont-Ferrand, France
PMH26 QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS IN SPAIN: ONE-YEAR FOLLOW-UP STUDY. SOHO STUDY
Prieto L1, Escobar R1, Bousoño M2, González-Torres M3, Mayoral F4, Montejo A5, Olivares J6, Ros S7, Sanjuan J8, 1Lilly, S.A, Alcobendas, Madrid, Spain; 2Universidad de Oviedo, Alcobendas, Madrid, Spain; 3Hospital de Basurto, Bilbao, Vizkaia, Spain; 4Complejo Hospitalario Carlos Haya, Málaga, Spain; 5Hospital Universitario de Salamanca, Salamanca, Spain; 6Complejo Hospitalario Xeral-Cies, Vigo, Pontevedra, Spain; 7Hospital del Mar, Barcelona, Spain; 8Universidad de Valencia, Alcobendas, Madrid, Spain
 

   
URINARY/KIDNEY DISEASES OR DISORDERS
  Urinary/Kidney Diseases or Disorders – Clinical Outcomes Studies
PUK1 THE USE OF A URINARY CATHETER REMINDER TO REDUCE URINARY CATHETERIZATION IN HOSPITALIZED PATIENTS
Saint S1, Kaufman S2, Thompson M2, Rogers M2, Chenoweth C2, 1Ann Arbor VA Medical Center and University of Michigan Medical School, Ann Arbor, MI, USA; 2University of Michigan, Ann Arbor, MI, USA
PUK2 TREATMENT PERSISTENCE OF OXYBUTYNIN XL AND TOLTERODINE IR IN A REAL-WORLD CLINICAL PRACTICE SETTING: DATA FROM THE UNITED KINGDOM
Feng W1, Dubois D2, Neslusan C1, Simons WR3, 1Johonson & Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA; 2Johnson & Johnson Pharmaceutical Services, LLC, Beerse, Belgium; 3Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA
PUK3 TREATMENTS RECEIVED FOR STRESS URINARY INCONTINENCE (SUI) SYMPTOMS BY PATIENTS SEEKING HELP WITHIN A UK PRIMARY CARE SETTING
Martin ML1, Bushnell DM1, Das Gupta RJ2, Assassa P3, Shaw C4, 1Health Research Associates, Inc, Mountlake Terrace, WA, USA; 2Eli Lilly UK, Basingstoke, Hampshire, United Kingdom; 3Mid Yorkshire Trust, Pontefract, United Kingdom; 4Chris Shaw, Newport Gwent, S Wales, United Kingdom
PUK4 TREATMENT OF URINARY INCONTINENCE IN DAILY PRACTICE DOES NOT COMPLY WITH THE GUIDELINES
Penning-van Beest FJA1, Sturkenboom MCJM2, Herings RMC1, 1PHARMO Institute, Utrecht, The Netherlands; 2Erasmus MC, Rotterdam, The Netherlands
 

  Urinary/Kidney Diseases or Disorders - Cost Studies
PUK5 COMPARISON OF THE DOSE AND COST OF EPREX BY ROUTE OF ADMINISTRATION
Trakas K, Robinson K, Janssen-Ortho Inc, Toronto, ON, Canada
PUK6 COST-MINIMIZATION ANALYSIS OF TENSION-FREE VAGINAL TAPE VS. OPEN BURCH COLPOSUSPENSION IN FEMALE STRESS URINARY INCONTINENCE
Lahoz R1, Magaz S2, Badia X2, Amat L3, Bielsa O4, Díez-Gómez E5, Fillol M6, Gálmes Í7, Santiago A8, Santisteban J9, 1Health Outcomes Policy And Economics, Barcelona, Spain; 2Health Outcomes Research Europe, Barcelona, Spain; 3Hospital Sant Joan De Deu, Barcelona, Spain; 4Hospital Nuestra Señora Del Mar, Barcelona, Spain; 5Hospital General Universitario Gregorio Marañón, Madrid, Spain; 6Hospital Vila-Real, Castellón, Spain; 7Hospital Universitario Santa Cristina, Madrid, Spain; 8Hospital Virgen Del Camino, Navarra, Spain; 9Hospital Universitario La Paz, Madrid, Spain
PUK7 DITROPAN XL VERSUS DETROL IN CANADA: ECONOMIC ANALYSIS
Getsios D1, Caro J2, Ishak K3, El-Hadi W3, Payne KA4, Luong D5, McMahon D6, 1Caro Research Institute, Halifax, NS, Canada; 2Caro Research Institute, Concord, MA, USA; 3Caro Research Institute, Dorval, QC, Canada; 4Caro Research Institute, Montreal, QC, Canada; 5Janssen Ortho Inc, Toronto, ON, Canada; 6Confex, Cumberland, RI, USA
PUK8 SEVELAMER USE IN HYPERPHOSPHATEMIA: HEALTH AND ECONOMIC CONSEQUENCES
Caro JJ1, Huybrechts KF1, Wilson DA2, London GM3, 1Caro Research Institute, Concord, MA, USA; 2Genzyme Corporation, Cambridge, MA, USA; 3Centre Hospitalier F.H. Manhès, Fleury-Mérogis, France
PUK9 ECONOMICAL IMPACT OF SACRAL NERVE STIMULATION THERAPY IN 62 PATIENTS WITH LOWER URINARY TRACT DYSFUNCTION
Cappellano F1, Bertapelle P2, Spreafico L3, del Popolo G4, Kocjancic E5, Donelli A6, Ponzi P7, Giardiello G7, Caprari F8, Catanzaro F1, 1Multimedica Milano, Sesto San Giovanni, Milan, Italy; 2CTO CRF-MA, Turin, Italy; 3E. Franchini Hospital, Montecchio Emilia, R E, Italy; 4Ospedale Careggi, Firenze, Italy; 5Ospedale Maggiore della Carità, Novara, Italy; 6Medtronic Europe, Tolochenaz, vaud, Switzerland; 7Medtronic Italy, Sesto San Giovanni, Milan, Italy; 8Centro Studi Fondazione Medtronic Italia, Sesto San Giovanni, Milan, Italy
PUK10 A COST ANALYSIS OF ALFUZOSIN IN THE MANAGEMENT OF ACUTE URINARY RETENTION
Lamotte M1, Massaer K2, Vranckx K2, Annemans L1, 1Ghent University, Meise, Belgium; 2Sanofi-Synthélabo, Brussel, Belgium
PUK11 SURVIVAL IN END-STAGE RENAL DISEASE (ESRD) PATIENTS: ECONOMIC CONSEQUENCES OF THE LACK OF AUTOLOGOUS ARTERIOVENOUS FISTULAE (AVF) AT THE START OF HEMODIALYSIS
Ortega T1, Moreno D1, Rebollo P1, Diaz C2, Valdés C1, Ortega F1, 1Hospital Central Universitario de Asturias and Institute "Reina Sofia" for Nephrological Research, Oviedo, Asturias, Spain; 2Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
PUK12 COMPARISON OF TACROLIMUS WITH CYCLOSPORIN IN KIDNEY TRANSPLANTATION: COST-MINIMISATION AND COST-EFFECTIVENESS ANALYSES
Schindler TM1, Klein WH2, McKechnie T3, 1Fujisawa GmbH, Munich, Germany; 2PharmaExperience, Neubiberg, Germany; 3The Lewin Group Quintiles Uk Ltd, Bracknell, United Kingdom
 

  Urinary/Kidney Diseases or Disorders – Quality of Life Studies
PUK13 COMPARISON OF THE PERFORMANCE AND DATA QUALITY OF ELECTRONIC AND PAPER DIARIES FOR BENIGN PROSTATIC HYPERPLASIA (BPH)
Bushnell DM1, Martin ML1, Hareendran A2, Abraham L2, 1Health Research Associates, Inc, Mountlake Terrace, WA, USA; 2Pfizer Ltd, Sandwich, United Kingdom
PUK14 "EFFECT SIZE" OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH CHRONIC ALLOGRAFT NEPHROPATHY AND ANEMIA TREATED WITH RH-EPO
Rebollo P1, Baltar JM1, Campistol JM2, Ortega T1, Ortega F1, 1Hospital Central de Asturias and Institute "Reina Sofia" for Nephrological Research, Oviedo, Asturias, Spain; 2Hospital Clinic i Provincial, Barcelona, Spain
PUK15 VALIDATION STUDY OF THE SPANISH VERSION OF THE ICIQ-SHORT FORM. A USEFUL INSTRUMENT IN DETECTING URINARY INCONTINENCE
Espuña M1, Rebollo P2, Puig M1, Pérez A1, 1Hospital Clinic. Universidad de Barcelona, Barcelona, Catalonia, Spain; 2Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
PUK16 LOWER IMPACT ON HEALTH RELATED QUALITY OF LIFE (HRQOL) IN ELDERLY PATIENS STARTING AND AFTER ONE YEAR OF HEMODIALYSIS (HD) THAN IN YOUNGER PATIENS: A PROSPECTIVE STUDY
Garcia-Mendoza M, Valdés C, Rebollo P, Ortega T, Moreno D, Ortega F, Hospital Central Universitario de Asturias and Institute "Reina Sofia" for Nephrological Research, Oviedo, Asturias, Spain
 

   
WOMEN’S & MEN’S HEALTH
  Women’s & Men’s Health – Clinical Outcomes Studies
PWH1 EFFECT OF ORAL LOW-DOSE HORMONAL REPLACEMENT THERAPY (COMBINED ESTRADIOL 1MG AND NORESTISTERONE ACETATE 0.5 MG) ON CARDIOVASCULAR RISK IN SPANISH POSTMENOPAUSAL WOMEN
Mirada A1, Barnés E2, López JS2, 1Laboratorios Isdin, Barcelona, Spain; 2Pharma-Consult, Barcelona, Spain
PWH2 EFFECTIVITY AND SAFETY OF ORAL LOW-DOSE HORMONAL REPLACEMENT THERAPY (COMBINED ESTRADIOL 1 MG AND NORETISTERONE 0.5 MG) IN CLIMACTERIC SYMPTOMS ON SPANISH POSTMENOPAUSAL WOMEN
López JS1, Barnés E1, Mirada A2, 1Pharma-Consult, Barcelona, Spain; 2Laboratorios Isdin, Barcelona, Spain
  Women’s & Men’s Health – Quality of Life Studies
PWH3 PULSED OESTROGEN THERAPY WITH INTRANASAL 17-B OESTRADIOL IMPROVES WOMEN'S QUALITY OF LIFE IN THE EARLY POSTMENOPAUSAL PERIOD
Szamatowicz M1, Jaworski R2, Bartminski W2, Czech M2, Pachocki R2, 1Medical University, Bialystok, Poland; 2Servier Poland Research Institute, Warsaw, Poland
PWH4 VASOMOTOR SYMPTOMS AND QUALITY OF LIFE (QOL) IN POSTMENOPAUSAL WOMEN
Bobula JD, Wyeth Research,Collegeville, PA,USA
PWH5 QUALITY OF LIFE (QOL) DIFFERENTIATION ANALYSIS IN PATIENTS UNDERGOING CONTROLLED OVARIAN STIMULATION (COS) WITH TWO DIFFERENT PREPARATIONS OF RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE (R-HFSH)
Beresniak A1, Brasseur P1, Daya S2, Silverberg K3, Wikland M4, Duru G5, Decostered G1, Brasseur P1, Blatz S6, 1Serono International SA, Geneva,Switzerland; 2Mc Master University, Hamilton,Ontario,Canada; 3Texas Fertility Center, Austin,TX,USA; 4Fertilitets centrum Goteborg, Goteborg,Sweden; 5Université Claude Bernard Lyon 1, Villeurbanne, France; 6Reproductive Medicine & Infertility Associates, Woodburry, MN,USA
 

PWH6 PATIENT AND PARTNER TREATMENT SATISFACTION SCALE (TSS) IN ERECTILE DYSFUNCTION
Kubin M1, Britt D2, Trudeua E3, Fugl-Meyer A4, Gondek K5, 1Bayer AG,Wuppertal,Germany; 2Bayer Pharmaceutical, West Haven,CT, USA; 3MAPI Values, Lyon, France; 4Uppsala University, Uppsala,Sweden; 5Bayer Pharmaceutical Corporation, West Haven,CT, USA
PWH7 A NEW INSTRUMENT TO MEASURE THE PSYCHOLOGICAL IMPACT OF ERECTILE DYSFUNCTION. VALIDATION OF A SPANISH VERSION OF THE JOHNSON AND MCCOY’S SELF-CONFIDENCE SCALE
Martin-Morales A1, Manero M2, Regadera L3, Artes M4, 1Hospital Carlos Haya,Málaga,Spain; 2Q.F. Bayer, Barcelona,Spain; 3GlaxoSmithKline,Madrid,Spain; 4Adelphi Targis S.L, Barcelona,Spain
PWH8 DEVELOPMENT AND INITIAL TESTING OF A NEW PATIENT-REPORTED QUESTIONNAIRE- ERECTION QUALITY SCALE
Wincze JP1, Fehnel SE2, McLeod LD2, Granger AL2, Merchant S3, 1Brown University, Providence,RI,USA; 2RTI-Health Solutions,Research Triangle Park,NC,USA; 3Bayer Pharmaceuticals Corporation, West Haven,CT, USA
 

   
HEALTH CARE POLICY
  Health Care Policy – Cost Evaluation Issues
PHP1 POTENTIAL FINANCIAL IMPACT OF ITEM RESPONSE THEORY'-BASED INDICATIONS FOR LONG-TERM HEALTH CARE FACILITIES
Dijkgraaf MGW, Lindeboom R,Academic Medical Center/University of Amsterdam,Amsterdam,The Netherlands
PHP2 AIDS AND ECONOMIC GROWTH: THE EPIDEMIC TRAP, THEORY AND CALIBRATION
Couderc N1, Ventelou B2, Drouhin N3, 1University of Paris 1-Panthéon Sorbonne and CNRS, Paris, France; 2OFCE, Paris, France; 3Ecole Normale Supérieure de Cachan, Cachan, France
PHP3 PERSPECTIVES AND BARRIERS IN THE DEVELOPMENT OF PHARMACOECONOMICS AND ITS APPLICATIONS IN POLAND- PRELIMINARY RESULTS OF A SURVEY
Czech M, Hermanowski T, Pachocki R, Warsaw University of Technology, Warsaw, Poland
PHP4 ARE THE RESULTS OF ECONOMIC EVALUATIONS GENERALIZABLE? EVIDENCE FROM STUDIES OF PHARMACEUTICALS IN WESTERN EUROPE
Barbieri M1, Drummond M1, Willke R2, Chancellor J1, Jolain B3, Towse A4, 1Innovus Research UK Ltd,High Wycombe,United Kingdom; 2Pfizer Inc, Peapack, NJ,USA;
PHP5 HOW PHARMACOECONOMICS INDICATORS FOR THERAPEUTIC INNOVATIONS IN ACUTE AND CHRONIC DISEASE CAN ASSIST PAYORS IN THE DECISION MAKING PROCESS
Woronoff Lemsi MC1, Jasso Mosqueda JG2, Pourriat JL3, Durand-zaleski I4, Desprez G5, Azoulay E6, Brion JP7, Miadi-Fargier H2, Chicoye A2, 1CHU Besançon,Besancon, France; 2Annie Chicoye Economics, Neuilly sur Seine, France; 3Hôpital de l'Hôtel Dieu, Paris, France; 4Henri Mondor Hospital, Créteil, France; 5Arh Pas De Calais,Lille, France; 6Hôpital Saint Louis, Paris, France; 7Chu Grenoble,La Tronche, France
 

  Health Care Policy – Cost Studies
PHP6 COMPARISON OF ACTUAL COSTS AND DRG-BASED REIMBURSEMENT OF INTENSIVE CARE IN GERMAN ICUS
Neilson A1, Moerer O2, Burchardi H2, Schneider H1, 1HealthEcon AG,Basel,Switzerland; 2Department of Anaesthesiology, Emergency and Intensive Care Medicine, University Hospital Gottingen,Gottingen,Germany
PHP7 PHARMACOECONOMICS IN HEALTH CARE-DECISION MAKING: A SURVEY ON CHINA HEALTH CARE SYSTEM
Yang L1, Hu S1, Mulligan A2, 1Fudan University, Shanghai, China; 2GSKChina, Shanghai, China
PHP8 THE EUROPEAN NETWORK OF HEALTH ECONOMIC EVALUATION DATABASES (EURO NHEED) PROJECT
Drummond MF1, Boulenger S2, Nixon J1, Ulmann P2, Glanville JM1, de Pouvourville G2, 1York University, York,England; 2Collège des Économistes de la Santé, Paris, France
PHP9 THE IMPACT OF CHANGING REIMBURSEMENT MECHANISMS : THE CASE OF PROPHYLAXIS IN BELGIAN HOSPITALS
Smet M, University of Antwerp, Antwerpen, Belgium
PHP10 HOSPITALIZATIONS FOR INJURIES RESULTING FROM CONTACT SPORTS: RESOURCE USE AND COSTS
O'Brien JA1, Duran PA1, Jacobs LMV, 1Caro Research Institute,Concord,MA,USA; 2University of Connecticut Medical School, Farmington,CT, USA
  Health Care Policy – Compliance Studies
PHP11 EFFECT OF COPAY INCREASE ON COMPLIANCE: A NATURAL EXPERIMENT
Meissner B, Shinogle JA, Kozma C,Shah M,University of South Carolina, Columbia,SC,USA
PHP12 THE ECONOMIC IMPLICATIONS OF NON-COMPLIANCE AFTER RENAL TRANSPLANTATION
Cleemput I1, De Geest S2, Vanrenterghem Y3, Kesteloot K4, 1Katholieke Universiteit Leuven,Leuven, Belgium; 2University of Basel,Basel,Switzerland; 3University Hospitals Leuven,Leuven,Belgium; 4Catholic University Leuven,Leuven,Belgium
 

  Health Care Policy – Drug/Price/Reimbursement Studies
PHP13 POLICIES FOR INCLUSION OF DRUGS FOR REIMBURSEMENT BY THE PHILIPPINE HEALTH INSURANCE CORPORATION
Valera MR, Philippine Health Insurance Corporation, Pasig,Metro Manila,Philippines
PHP14 DRUG PRICE INDICES 1980-2002 IN FINLAND
Jormanainen V1, Hahl J1, Aaltonen S2, 1GlaxoSmithKline,Espoo, Finland; 2Pharma Industry Finland,Helsinki, Finland
PHP15 COMPARISON OF MARKET EXCLUSIVITY OF PHARMACEUTICALS IN CANADA,THE UNITED STATES,THE UNITED KINGDOM AND FRANCE
Palmer WN, Neale S,Salazar A, Palmer D'Angelo Consulting Inc, Ottawa,ON,Canada
PHP16 SPANISH NATIONAL HEALTH SERVICE: ANALYSIS OF THE INTRODUCTION OF NEW DRUGS IN THE CLINICAL PRACTICE FROM 1996 TO 2000
Gaspar M, Modamio P, Lastra C, Mariño E,University of Barcelona,Barcelona,Spain
PHP17 SURVEY ON DRUG VALUE ASSESSMENT AMONG PRESCRIBERS AND PAYERS IN ITALIAN HOSPITALS
Negrini C, D'Ausilio A,Lopatriello S,Berto P, PBE Consulting, Verona,Italy
PHP18 REIMBURSING OFFICE-BASED DRUG MANAGEMENT COSTS: POLICY OPTIONS
Baker JJ, Resource Group,Ltd,Pickton,TX,USA
PHP19 CONSUMER VALUATION OF PRESCRIPTION DRUG BENEFIT PLANS
Taylor SD1, McKercher PL1, Gagnon JP2, 1University of Michigan,Ann Arbor, MI,USA; 2Aventis Pharmaceuticals Inc, Bridgewater, NJ,USA
PHP20 MARKET SHARE AND CHARACTERISTICS OF GENERIC DRUGS IN GREECE
Geitona M, Kyriopoulos J,Zavras D,Karamouzis J,National School of Public Health,Athens, Greece
PHP21 IMPACT OF PHARMACY INTERVENTIONS ON QUALITY OF HOSPITAL PRESCRIBING: INTERVENTIONS AND COST SAVINGS ASSESSMENT
Hsu C, Kuo H, Tai C,Chang Gung Memorial Hospital, Kaohsiung, Taiwan
PHP22 AN INVESTIGATION OF GENERIC DRUG UTILISATION AND POTENTIAL SAVINGS FROM GENERIC SUBSTITUTION IN THE IRISH HEALTH CARE SETTING
Tilson L1, McGowan B1, Bennett K2, Ryan M1, Barry M1, 1National Centre for Pharmacoeconomics,James's St,Ireland; 2Trinity Centre for Health Sciences,Dublin,Ireland
PHP23 THE DRUG PRICE REFERENCE INDEX STUDY OF THE PHILIPPINE HEALTH INSURANCE CORPORATION
Valera MR, Roan GM,Dequito AB, Palafox B, Banzon EP, Wong JQ, Philippine Health Insurance Corporation, Pasig,Metro Manila,Philippines
PHP24 THE VALUE OF BOARD OF PHARMACEUTICAL SPECIALTY CERTIFICATION: RESOURCE USE AND DECISION-MAKING
Ryan M, Romanelli F, Smith KM,Cain JJ,University of Kentucky, Lexington,KY, USA
 

  Health Care Policy – Health System Studies
PHP25 MECHANISMS AND OUTCOMES OF UTILIZATION REVIEW CONDUCTED AMONG PHIC-ACCREDITED HEALTH CARE FACILITIES IN THE PHILIPPINES
Valera MR, Soria FZ, Lavina SMS, Laureta-Barbaza JA, Banting MPC, Calces AAC, Philippine Health Insurance Corporation, Pasig,Rizal,Philippines
PHP26 INTENSIVIST PRACTICE CHANGE IN GLUCOSE CONTROL FOR CRITICALLY ILL PATIENTS
Conner T1, Drosu D1, Krstic B1, Rankin S1, Newby C1, Rascati K2, Flesner K1, Weingarten J1, 1Brackenridge Hospital,Austin,TX,USA; 2University of Texas at Austin, Austin,TX,USA
PHP27 THE ASSOCIATION OF RECOMMENDED SURGICAL SITE INFECTION GUIDELINES AND OTHER FACTORS WITH HOSPITAL LENGTH OF STAY (LOS) IN PATIENTS UNDERGOING DIFFERENT CLEAN OR CLEAN-CONTAMINATED PROCEDURES
Bonnet PO1, Barlev A1, Johnson KA1, Hopefl A2, 1University of Southern California,Los Angeles,CA,USA; 2AmeriNet,St. Louis,MO,USA
PHP28 COST-BENEFIT ANALYSIS OF A STATE POISON CENTER
Reeder CE, Michels JE, University of South Carolina,Columbia,SC,USA
PHP29 WHERE DOES THE GERMAN HEALTH CARE SYSTEM WANT TO GO TO?
Naujoks C1, Kohlmann T2, 1Novartis Pharma AG,Basel, Switzerland; 2University of Greifswald,Greifswald,MV, Germany
PHP30 THE IMPLICATIONS OF THE USE OF TUBE FEEDING IN THE UK SECONDARY HEALTH CARE SYSTEM
Girod I1, Pang F2, Saleh A1, Edington J2, 1Mapi Values, Macclesfield, Cheshire, United Kingdom; 2Abbott UK, Maidenhead, Berkshire, United Kingdom
 

  Health Care Policy – New Health Technology Studies
PHP31 PAYMENTS FOR HIGH COST NEW TECHNOLOGY DRUGS AND BIOLOGICALS IN THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM: POLICY IMPLICATIONS
Baker JJ, University of Rochester, Pickton,TX,USA
PHP32 MANAGING TECHNOLOGICAL INNOVATION IN THE HEALTH CARE SECTOR
Haycox AR, University of Liverpool,Liverpool,United Kingdom
PHP33 EVALUATION AND SELECTION OF MEDICAL HEALTH TECHNOLOGIES: A GROUP DECISION SUPPORT SYSTEM (GDSS)
Cantor E, Shtub A, Israel Medical Association,Ramat-Gan,Israel
PHP34 THE EFFECTS OF GENETIC TESTING ON THE DEMAND FOR LIFE INSURANCE
Witt JC, University of Guelph,Guelph,ON,Canada
PHP35 SMOKING CESSATION: RELEVANCE IN THE UNDER 25 GROUP
Taïeb C1, Piergiovanni J2, Randhaxe G3, Myon E1, 1Pharmaco Economics & Quality of Life Department,Boulogne Billancourt, France; 2Centre de formation Ste Cecile,Albi, France; 3Pierre Fabre Santé,Boulogne Billancourt, France
  Health Care Policy – Patient Reported Outcomes Studies
PHP36 A MULTIDIMENSIONAL HEALTH CARE INTERVENTION APPRAISAL: THE CO-ORDINATED PALLIATIVE CARE NETWORK "QUIETUDE"
Jasso Mosqueda JG1, Diez F2, Chen-Li-Kwang N1, Chippeaux S2, Lacour F2, Lassaunière JM3, Vinant P4, Chicoye A1, 1Annie Chicoye Economics,Neuilly sur Seine, France; 2Réseau Quiétude, Paris, France; 3Hôpital de l'Hôtel Dieu, Paris, France; 4Hôpital Cochin, Paris, France
PHP37 USING PATIENT REPORTED OUTCOMES (PRO) DATA TO SEGMENT HEALTH CARE CONSUMERS AND UNCOVER THEIR RECEPTIVENESS TO PHARMACEUTICAL ADVERTISING
Edmondson M, McDonnell D,Consumer Health Sciences, Princeton, NJ, USA
 

   Poster Presentations – Session II


6th European Congress Main Page

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2014 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.